153 related articles for article (PubMed ID: 29715114)
1. Disparities of Immunotherapy Utilization in Patients with Stage III Cutaneous Melanoma: A National Perspective.
Al-Qurayshi Z; Crowther JE; Hamner JB; Ducoin C; Killackey MT; Kandil E
Anticancer Res; 2018 May; 38(5):2897-2901. PubMed ID: 29715114
[TBL] [Abstract][Full Text] [Related]
2. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.
Amini A; Rusthoven CG; Waxweiler TV; Jones BL; Fisher CM; Karam SD; Raben D
J Am Acad Dermatol; 2016 Feb; 74(2):309-16. PubMed ID: 26670715
[TBL] [Abstract][Full Text] [Related]
3. Is sex an independent prognostic factor in cutaneous head and neck melanoma?
Arce PM; Camilon PR; Stokes WA; Nguyen SA; Lentsch EJ
Laryngoscope; 2014 Jun; 124(6):1363-7. PubMed ID: 24122966
[TBL] [Abstract][Full Text] [Related]
4. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
6. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
7. Improved Survival with Immunotherapy but Lack of Synergistic Effect with Radiation for Stage IV Melanoma of the Head and Neck.
Babcock B; Rodrigues M; Kearns D; Solomon N; Reeves ME; Senthil M; Garberoglio CA; Namm JP
Am Surg; 2019 Oct; 85(10):1118-1124. PubMed ID: 31657306
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
9. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma.
Klebaner D; Saddawi-Konefka R; Finegersh A; Yan CH; Califano JA; London NR; Deconde AS; Faraji F
Int Forum Allergy Rhinol; 2020 Sep; 10(9):1087-1095. PubMed ID: 32623838
[TBL] [Abstract][Full Text] [Related]
11. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden.
Eriksson H; Lyth J; Månsson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Eur J Cancer; 2013 Aug; 49(12):2705-16. PubMed ID: 23583439
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-based follow-up does not increase survival in early-stage melanoma patients: A comparative cohort study.
Ribero S; Podlipnik S; Osella-Abate S; Sportoletti-Baduel E; Manubens E; Barreiro A; Caliendo V; Chavez-Bourgeois M; Carrera C; Cassoni P; Malvehy J; Fierro MT; Puig S
Eur J Cancer; 2017 Nov; 85():59-66. PubMed ID: 28888850
[TBL] [Abstract][Full Text] [Related]
13. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
Haque W; Verma V; Butler EB; Teh BS
J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
15. Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma.
Tella SH; Kommalapati A; Ganti AK; Marr AS
J Natl Compr Canc Netw; 2019 Nov; 17(11):1334-1342. PubMed ID: 31693989
[TBL] [Abstract][Full Text] [Related]
16. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
17. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.
Zell JA; Cinar P; Mobasher M; Ziogas A; Meyskens FL; Anton-Culver H
J Clin Oncol; 2008 Jan; 26(1):66-75. PubMed ID: 18165642
[TBL] [Abstract][Full Text] [Related]
18. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
19. Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma.
Tejera-Vaquerizo A; Nagore E; Puig S; Robert C; Saiag P; Martín-Cuevas P; Gallego E; Herrera-Acosta E; Aguilera J; Malvehy J; Carrera C; Cavalcanti A; Rull R; Vilalta-Solsona A; Lannoy E; Boutros C; Benannoune N; Tomasic G; Aegerte P; Vidal-Sicart S; Palou J; Alos LL; Requena C; Traves V; Pla Á; Bolumar I; Soriano V; Guillén C; Herrera-Ceballos E
Eur J Cancer; 2015 Sep; 51(13):1780-93. PubMed ID: 26072362
[TBL] [Abstract][Full Text] [Related]
20. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
